Camlin Fine Sciences Past Earnings Performance
Past criteria checks 0/6
Camlin Fine Sciences's earnings have been declining at an average annual rate of -44.2%, while the Chemicals industry saw earnings growing at 14.6% annually. Revenues have been growing at an average rate of 11.1% per year.
Key information
-44.2%
Earnings growth rate
-44.2%
EPS growth rate
Chemicals Industry Growth | 17.7% |
Revenue growth rate | 11.1% |
Return on equity | -37.1% |
Net Margin | -13.9% |
Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
A Piece Of The Puzzle Missing From Camlin Fine Sciences Limited's (NSE:CAMLINFINE) 26% Share Price Climb
Nov 27Camlin Fine Sciences (NSE:CAMLINFINE) Will Be Hoping To Turn Its Returns On Capital Around
Oct 19Camlin Fine Sciences (NSE:CAMLINFINE) Has A Somewhat Strained Balance Sheet
Mar 29Positive Sentiment Still Eludes Camlin Fine Sciences Limited (NSE:CAMLINFINE) Following 26% Share Price Slump
Mar 29Is There An Opportunity With Camlin Fine Sciences Limited's (NSE:CAMLINFINE) 31% Undervaluation?
Sep 02Is It Time To Consider Buying Camlin Fine Sciences Limited (NSE:CAMLINFINE)?
Apr 06Rainbows and Unicorns: Camlin Fine Sciences Limited (NSE:CAMLINFINE) Analysts Just Became A Lot More Optimistic
Feb 19Camlin Fine Sciences Limited Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next
Nov 17Should You Think About Buying Camlin Fine Sciences Limited (NSE:CAMLINFINE) Now?
Oct 15Camlin Fine Sciences Limited (NSE:CAMLINFINE) Shares Could Be 32% Below Their Intrinsic Value Estimate
Jan 15Returns On Capital At Camlin Fine Sciences (NSE:CAMLINFINE) Paint A Concerning Picture
Jan 04Why Camlin Fine Sciences Limited (NSE:CAMLINFINE) Could Be Worth Watching
Nov 30Investors Could Be Concerned With Camlin Fine Sciences' (NSE:CAMLINFINE) Returns On Capital
Oct 05At ₹163, Is Camlin Fine Sciences Limited (NSE:CAMLINFINE) Worth Looking At Closely?
Aug 20Estimating The Intrinsic Value Of Camlin Fine Sciences Limited (NSE:CAMLINFINE)
Jun 30Camlin Fine Sciences (NSE:CAMLINFINE) Takes On Some Risk With Its Use Of Debt
Feb 26What Is Camlin Fine Sciences Limited's (NSE:CAMLINFINE) Share Price Doing?
Feb 15Is Camlin Fine Sciences Limited (NSE:CAMLINFINE) Popular Amongst Insiders?
Feb 05Camlin Fine Sciences (NSE:CAMLINFINE) Shareholders Booked A 29% Gain In The Last Year
Jan 26Here's What To Make Of Camlin Fine Sciences' (NSE:CAMLINFINE) Returns On Capital
Jan 16Don't Ignore The Fact That This Insider Just Sold Some Shares In Camlin Fine Sciences Limited (NSE:CAMLINFINE)
Jan 06Should You Be Adding Camlin Fine Sciences (NSE:CAMLINFINE) To Your Watchlist Today?
Jan 04Can Mixed Fundamentals Have A Negative Impact on Camlin Fine Sciences Limited (NSE:CAMLINFINE) Current Share Price Momentum?
Dec 24How Should Investors React To Camlin Fine Sciences' (NSE:CAMLINFINE) CEO Pay?
Dec 13Does Camlin Fine Sciences's (NSE:CAMLINFINE) Statutory Profit Adequately Reflect Its Underlying Profit?
Dec 02Camlin Fine Sciences (NSE:CAMLINFINE) Takes On Some Risk With Its Use Of Debt
Nov 21Is Now An Opportune Moment To Examine Camlin Fine Sciences Limited (NSE:CAMLINFINE)?
Nov 09The Camlin Fine Sciences (NSE:CAMLINFINE) Share Price Is Up 49% And Shareholders Are Holding On
Oct 27What Do The Returns On Capital At Camlin Fine Sciences (NSE:CAMLINFINE) Tell Us?
Oct 14Camlin Fine Sciences Limited's (NSE:CAMLINFINE) 29% Price Boost Is Out Of Tune With Earnings
Oct 01Here's Why I Think Camlin Fine Sciences (NSE:CAMLINFINE) Might Deserve Your Attention Today
Sep 30What Kind Of Shareholders Hold The Majority In Camlin Fine Sciences Limited's (NSE:CAMLINFINE) Shares?
Sep 17Read This Before Judging Camlin Fine Sciences Limited's (NSE:CAMLINFINE) ROE
Sep 04Revenue & Expenses Breakdown
How Camlin Fine Sciences makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
30 Sep 24 | 16,064 | -2,231 | 2,406 | 0 |
30 Jun 24 | 15,893 | -1,423 | 2,315 | 0 |
31 Mar 24 | 16,131 | -928 | 2,242 | 0 |
31 Dec 23 | 16,381 | -8 | 1,931 | 0 |
30 Sep 23 | 16,400 | 350 | 1,893 | 0 |
30 Jun 23 | 17,174 | 674 | 1,850 | 0 |
31 Mar 23 | 16,816 | 577 | 1,823 | 0 |
31 Dec 22 | 16,441 | 581 | 1,727 | 0 |
30 Sep 22 | 16,371 | 628 | 1,710 | 0 |
30 Jun 22 | 14,650 | 442 | 1,666 | 0 |
31 Mar 22 | 14,121 | 650 | 1,582 | 0 |
31 Dec 21 | 13,495 | 598 | 1,521 | 0 |
30 Sep 21 | 12,666 | 465 | 1,436 | 0 |
30 Jun 21 | 12,122 | 579 | 1,375 | 0 |
31 Mar 21 | 11,871 | 510 | 1,301 | 0 |
31 Dec 20 | 11,533 | 394 | 1,312 | 0 |
30 Sep 20 | 11,293 | 291 | 1,255 | 0 |
30 Jun 20 | 10,948 | 302 | 1,207 | 0 |
31 Mar 20 | 10,491 | 303 | 1,180 | 0 |
31 Dec 19 | 10,243 | 349 | 1,170 | 0 |
30 Sep 19 | 9,918 | 277 | 1,139 | 0 |
30 Jun 19 | 9,709 | 221 | 1,121 | 0 |
31 Mar 19 | 8,922 | 6 | 1,092 | 0 |
31 Dec 18 | 8,523 | -139 | 1,053 | 0 |
30 Sep 18 | 8,186 | -222 | 1,016 | 0 |
30 Jun 18 | 7,634 | -277 | 969 | 0 |
31 Mar 18 | 7,206 | -338 | 935 | 0 |
31 Dec 17 | 6,403 | -367 | 865 | 20 |
30 Sep 17 | 5,676 | -311 | 843 | 20 |
30 Jun 17 | 5,347 | -275 | 820 | 22 |
31 Mar 17 | 5,339 | -128 | 820 | 0 |
31 Dec 16 | 5,149 | 98 | 737 | 21 |
30 Sep 16 | 5,013 | 174 | 649 | 21 |
30 Jun 16 | 5,063 | 232 | 496 | 21 |
31 Mar 16 | 4,893 | 358 | 562 | 21 |
31 Dec 15 | 5,083 | 445 | 879 | 25 |
30 Sep 15 | 5,238 | 463 | 906 | 25 |
30 Jun 15 | 5,531 | 552 | 883 | 25 |
31 Mar 15 | 5,583 | 550 | 516 | 25 |
31 Mar 14 | 5,087 | 287 | 344 | 27 |
Quality Earnings: CAMLINFINE is currently unprofitable.
Growing Profit Margin: CAMLINFINE is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: CAMLINFINE is unprofitable, and losses have increased over the past 5 years at a rate of 44.2% per year.
Accelerating Growth: Unable to compare CAMLINFINE's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: CAMLINFINE is unprofitable, making it difficult to compare its past year earnings growth to the Chemicals industry (8%).
Return on Equity
High ROE: CAMLINFINE has a negative Return on Equity (-37.1%), as it is currently unprofitable.